drugset / Trial / NCT00143377

Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB

NCT00143377

Phase 4 Completed 600 enrolled Viatris Inc. Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.

Timeline

Start
2004-09
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule 4 mg

Indications